Denileukin diftitox as novel targeted therapy for lymphoid malignancies (Q36946771)

17 August 2017

1 reference

title

Denileukin diftitox as novel targeted therapy for lymphoid malignancies (English)

1 reference

17 August 2017

Bryan Y Wong

1

1 reference

17 August 2017

Stephanie A Gregory

series ordinal

2

1 reference

17 August 2017

Nam H Dang

series ordinal

3

1 reference

17 August 2017

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

25

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

495-501

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

17 August 2017

1 reference

The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

The interleukin-2 fusion protein, DAB389IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07357900701360096

10.1080/07357900701360096

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference